URGN Q4 2024 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+4.4% YoY

Gross Profit

$22M89.9% margin

Operating Income

-$28M-112.6% margin

Net Income

-$38M-152.7% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

-2.5%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$286M

Total Liabilities

$295M

Stockholders' Equity

-$9M

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$24M	+4.4%
Gross Profit	$22M	$21M	+4.0%
Operating Income	-$28M	-$15M	-89.3%
Net Income	-$38M	-$26M	-44.2%

Revenue Segments

Jelmyto

$46M100%